PRESS RELEASE published on 06/24/2024 at 22:05, 1 year 10 months ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of the general meeting, including board appointments and auditor reappointment. Shareholders voted in favor of all proposals Appointments Voting Results General Meeting CureVac Auditor Reappointment
BRIEF published on 05/28/2024 at 13:05, 1 year 11 months ago CureVac Announces Dosing of First Participant in Phase 2 Influenza Study GSK MRNA Technology Phase 2 Study CureVac Influenza Vaccine
BRIEF published on 05/28/2024 at 13:05, 1 year 11 months ago CureVac annonce le dosage du premier participant à l'étude de phase 2 sur la grippe GSK Technologie ARNm Étude De Phase 2 CureVac Vaccin Contre La Grippe
PRESS RELEASE published on 05/28/2024 at 13:00, 1 year 11 months ago CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CureVac initiates Phase 2 study in collaboration with GSK for seasonal influenza vaccine, targeting improved immune responses against influenza B strain GSK Vaccine Development Phase 2 Study CureVac Seasonal Influenza
BRIEF published on 05/23/2024 at 13:05, 1 year 11 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Financial Results Business Update Q1 2024 CureVac FDA Fast Track
BRIEF published on 05/23/2024 at 13:05, 1 year 11 months ago CureVac annonce ses résultats financiers pour le premier trimestre 2024 et fait le point sur ses activités Résultats Financiers Mise À Jour De L'entreprise T1 2024 CureVac Procédure Accélérée De La FDA
PRESS RELEASE published on 05/23/2024 at 13:00, 1 year 11 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRIEF published on 04/24/2024 at 13:11, 2 years ago CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRIEF published on 04/24/2024 at 13:11, 2 years ago CureVac annonce ses résultats financiers pour 2023 et des mises à jour stratégiques sur ses activités Technologie ARNm CureVac Collaborations Pharmaceutiques Vaccins Contre L'oncologie Vaccins Prophylactiques
BRIEF published on 04/24/2024 at 13:08, 2 years ago CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
Published on 05/13/2026 at 08:05, 11 minutes ago Tocvan Announces New Surface Gold-Silver Results, Outlining New Target 3 Kilometers East of Main Zone at Gran Pilar Gold-Silver Project
Published on 05/13/2026 at 00:00, 8 hours 16 minutes ago Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Published on 05/12/2026 at 23:35, 8 hours 41 minutes ago Infield Minerals Closes $1.25 Million Financing
Published on 05/12/2026 at 21:55, 10 hours 21 minutes ago UraniumX Discovery Corp Announces Option Agreement with Gold'n Futures
Published on 05/13/2026 at 08:05, 10 minutes ago BLUETTI Launches Smart Integrated Balcony Solar Solutions in Paris
Published on 05/13/2026 at 08:00, 16 minutes ago JOST delivers record quarter in Q1 2026: JOST boosts revenue and earnings achieving its strategic profitability target range
Published on 05/13/2026 at 08:00, 16 minutes ago CANCOM SE: CANCOM significantly increases operating profitability in Q1.26
Published on 05/13/2026 at 06:55, 1 hour 21 minutes ago Recticel Group realiseert doorbraak in PIR circulariteit met gerecycleerde polyol
Published on 05/13/2026 at 06:55, 1 hour 21 minutes ago Recticel Group closes the loop on PIR circularity with industrial scale recycled polyol plant
Published on 05/12/2026 at 18:15, 14 hours 1 minute ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/04/2026
Published on 05/12/2026 at 18:15, 14 hours 1 minute ago AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2026
Published on 05/12/2026 at 18:10, 14 hours 6 minutes ago imerys-12-05-2026-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-12-mai-2026
